Explore the vast range of titles available.

Interleukin-1β (IL-1β) is abundant in the tumor microenvironment, where this cytokine can promote tumor growth, but also antitumor activities. We studied IL-1β during early tumor progression using a model of orthotopically introduced 4T1 breast cancer cells. Whereas there is tumor progression and spontaneous metastasis in wild-type (WT) mice, in IL-1β–deficient mice, tumors begin to grow but subsequently regress. This change is due to recruitment and differentiation of inflammatory monocytes in the tumor microenvironment. In WT mice, macrophages heavily infiltrate tumors, but in IL-1β–deficient mice, low levels of the chemokine CCL2 hamper recruitment of monocytes and, together with low levels of colony-stimulating factor-1 (CSF-1), inhibit their differentiation into macrophages. The low levels of macrophages in IL-1β–deficient mice result in a relatively high percentage of CD11b⁺ dendritic cells (DCs) in the tumors. In WT mice, IL-10 secretion from macrophages is dominant and induces immunosuppression and tumor progression; in contrast, in IL-1β–deficient mice, IL-12 secretion by CD11b⁺ DCs prevails and supports antitumor immunity. The antitumor immunity in IL-1β–deficient mice includes activated CD8⁺ lymphocytes expressing IFN-γ, TNF-α, and granzyme B; these cells infiltrate tumors and induce regression. WT mice with 4T1 tumors were treated with either anti–IL-1β or anti–PD-1 Abs, each of which resulted in partial growth inhibition. However, treating mice first with anti–IL-1β Abs followed by anti–PD-1 Abs completely abrogated tumor progression. These data define microenvironmental IL-1β as a master cytokine in tumor progression. In addition to reducing tumor progression, blocking IL-1β facilitates checkpoint inhibition.

Cellular immunotherapies represent a promising approach for the treatment of cancer. Engineered adoptive cell therapies redirect and augment a leukocyte’s inherent ability to mount an immune response by introducing novel anti-tumor capabilities and targeting moieties. A prominent example of this approach is the use of T cells engineered to express chimeric antigen receptors (CARs), which have demonstrated significant efficacy against some hematologic malignancies. Despite increasingly sophisticated strategies to harness immune cell function, efficacy against solid tumors has remained elusive for adoptive cell therapies. Amongst cell types used in immunotherapies, however, macrophages have recently emerged as prominent candidates for the treatment of solid tumors. In this review, we discuss the use of monocytes and macrophages as adoptive cell therapies. Macrophages are innate immune cells that are intrinsically equipped with broad therapeutic effector functions, including active trafficking to tumor sites, direct tumor phagocytosis, activation of the tumor microenvironment and professional antigen presentation. We focus on engineering strategies for manipulating macrophages, with a specific focus on CAR macrophages (CAR-M). We highlight CAR design for macrophages, the production of CAR-M for adoptive cell transfer, and clinical considerations for their use in treating solid malignancies. We then outline recent progress and results in applying CAR-M as immunotherapies. The recent development of engineered macrophage-based therapies holds promise as a key weapon in the immune cell therapy armamentarium.

In contrast to the past reliance on morphology, the identification and enumeration of blood monocytes are nowadays done with monoclonal antibodies and flow cytometry and this allows for subdivision into classical, intermediate, and non-classical monocytes. Using specific cell surface markers, dendritic cells in blood can be segregated from these monocytes. While in the past, changes in monocyte numbers as determined in standard hematology counters have not had any relevant clinical impact, the subset analysis now has uncovered informative changes that may be used in management of disease.

In a nomenclature proposal published in 2010 monocytes were subdivided into classical and non-classical cells and in addition an intermediate monocyte subset was proposed. Over the last couple of years many studies have analyzed these intermediate cells, their characteristics have been described, and their expansion has been documented in many clinical settings. While these cells appear to be in transition from classical to non-classical monocytes and hence may not form a distinct cell population in a strict sense, their separate analysis and enumeration is warranted in health and disease.

Monocytes and macrophages are critical effectors and regulators of inflammation and the innate immune response, the immediate arm of the immune system. Dendritic cells initiate and regulate the highly pathogen-specific adaptive immune responses and are central to the development of immunologic memory and tolerance. Recent in vivo experimental approaches in the mouse have unveiled new aspects of the developmental and lineage relationships among these cell populations. Despite this, the origin and differentiation cues for many tissue macrophages, monocytes, and dendritic cell subsets in mice, and the corresponding cell populations in humans, remain to be elucidated.

Dengue virus (DENV) infection in children exhibits varied clinical presentations, wherein the role of monocytes is important in the innate immune response. In this study, laboratory-confirmed DENV pediatric patients ( n  = 120), with DENV-2 infection, were categorized into dengue fever (DF), dengue with warning signs (DWS) and severe dengue (SD) were assessed for monocyte subpopulation analysis using immunophenotyping involving CD14 and CD16 host-surface markers. Molecular docking was performed using HADDOCK 2.4 to analyze the interactions between CD14, CD16 and DENV envelope and capsid proteins. Among the cases, 84 (70%) were classified as DF and 36 (30%) as DWS & SD. Hematological and biochemical parameters indicated that thrombocytopenia and elevated hematocrit (> 40%) were significantly more common in DWS & SD, with markedly elevated liver enzymes (ALT and AST) in severe cases. Classical monocytes (CM-CD14++ CD16−) constituted 72.51% and 66.25% of the monocyte population in DF and DWS & SD cases, respectively. Intermediate monocytes (IM-CD14+ CD16+) comprised 9.89% and 30.86% in DF and DWS & SD cases, respectively. Non-classical monocytes (NCM-CD14+ CD16++) comprised 5.75% and 8.12% in DWS & SD and DF cases, respectively. In silico analysis revealed host CD16 and CD14 exhibited potential interactions with DENV capsid and envelope proteins, with binding energies − 8.9, − 10.1, − 8.6, and − 11.1 kcal/mol, respectively. IM was significantly increased in DWS & SD compared to DF ( p  < 0.05). These findings suggest that IM could act as host markers of DENV severity in children.

Psychosocial stress has profound effects on the body, including the immune system and the brain 1 , 2 . Although a large number of pre-clinical and clinical studies have linked peripheral immune system alterations to stress-related disorders such as major depressive disorder (MDD) 3 , the underlying mechanisms are not well understood. Here we show that expression of a circulating myeloid cell-specific proteinase, matrix metalloproteinase 8 (MMP8), is increased in the serum of humans with MDD as well as in stress-susceptible mice following chronic social defeat stress (CSDS). In mice, we show that this increase leads to alterations in extracellular space and neurophysiological changes in the nucleus accumbens (NAc), as well as altered social behaviour. Using a combination of mass cytometry and single-cell RNA sequencing, we performed high-dimensional phenotyping of immune cells in circulation and in the brain and demonstrate that peripheral monocytes are strongly affected by stress. In stress-susceptible mice, both circulating monocytes and monocytes that traffic to the brain showed increased Mmp8 expression following chronic social defeat stress. We further demonstrate that circulating MMP8 directly infiltrates the NAc parenchyma and controls the ultrastructure of the extracellular space. Depleting MMP8 prevented stress-induced social avoidance behaviour and alterations in NAc neurophysiology and extracellular space. Collectively, these data establish a mechanism by which peripheral immune factors can affect central nervous system function and behaviour in the context of stress. Targeting specific peripheral immune cell-derived matrix metalloproteinases could constitute novel therapeutic targets for stress-related neuropsychiatric disorders. Serum MMP8 is increased in stress-susceptible mice following chronic stress and leads to brain structure and behavioural changes in mice.

An atypical monocyte with partial granulocyte characteristics is identified and shown to be critical for the development of fibrosis. An immunological cell type inducing liver fibrosis In this study, Shizuo Akira and colleagues identify a previously unknown monocyte–granulocyte hybrid cell type as being critical to the development of bleomycin-induced pulmonary fibrosis in mice, the most commonly used experimental study model of human lung fibrosis. The cells, termed segregated-nucleus-containing atypical monocytes (SatMs), are differentiated from committed progenitor cells under the control of the transcription factor C/EBPβ. The authors speculate that SatMs, and other reported 'disorder-specific monocyte/macrophage subtypes' corresponding to certain diseases, might be investigated as highly specific therapeutic targets. Monocytes and macrophages comprise a variety of subsets with diverse functions 1 , 2 , 3 , 4 , 5 . It is thought that these cells play a crucial role in homeostasis of peripheral organs, key immunological processes and development of various diseases. Among these diseases, fibrosis is a life-threatening disease of unknown aetiology. Its pathogenesis is poorly understood, and there are few effective therapies. The development of fibrosis is associated with activation of monocytes and macrophages 6 , 7 , 8 . However, the specific subtypes of monocytes and macrophages that are involved in fibrosis have not yet been identified. Here we show that Ceacam1 + Msr1 + Ly6C − F4/80 − Mac1 + monocytes, which we term segregated-nucleus-containing atypical monocytes (SatM), share granulocyte characteristics, are regulated by CCAAT/enhancer binding protein β (C/EBPβ), and are critical for fibrosis. Cebpb deficiency results in a complete lack of SatM. Furthermore, the development of bleomycin-induced fibrosis, but not inflammation, was prevented in chimaeric mice with Cebpb −/− haematopoietic cells. Adoptive transfer of SatM into Cebpb −/− mice resulted in fibrosis. Notably, SatM are derived from Ly6C − FcεRI + granulocyte/macrophage progenitors, and a newly identified SatM progenitor downstream of Ly6C − FcεRI + granulocyte/macrophage progenitors, but not from macrophage/dendritic-cell progenitors. Our results show that SatM are critical for fibrosis and that C/EBPβ licenses differentiation of SatM from their committed progenitor.

Key Points Monocytes are a heterogeneous population of myeloid cells that originate from progenitors in the bone marrow and traffic via the bloodstream to peripheral tissues. Monocyte recruitment is guided by chemokines that bind to receptors expressed on the monocyte cell surface. The process is believed to follow a general paradigm of leukocyte adhesion and trafficking, and thus depends on the interactions of various adhesion molecules. Circulating monocytes traffic into tissues during both homeostasis and inflammation. When conditioned by local growth factors, pro-inflammatory cytokines and microbial products, monocytes can differentiate into macrophage or dendritic cell populations. The recruitment of monocytes is essential for effective control and clearance of bacterial, protozoal, fungal and viral infections, but recruited monocytes can also be deleterious and cause immunopathology during certain infections. Monocyte recruitment contributes to the pathogenesis of aseptic inflammatory diseases. Different subsets of monocytes are recruited to the aorta during atherosclerosis and possibly have distinct roles at this site. Monocyte egress from the bone marrow depends on CC-chemokine receptor 2 (CCR2), a chemokine receptor that binds to CC-chemokine ligand 2 (CCL2) and CCL7. Sensitive detection of circulating microbial molecules or pro-inflammatory cytokines by bone marrow-resident cells (such as mesenchymal stem cells and CXCL12-abundant reticular cells), with commensurate induction of CCL2, provides a mechanism to modulate the frequency of circulating inflammatory monocytes. This suggests that microorganisms may drive inflammatory disease in an otherwise 'sterile' tissue environment. Monocytes serve as precursors for various tissue macrophage and dendritic cell populations and contribute to both protective and pathological immune responses. Here, the authors describe the mechanisms that are involved in mobilizing monocytes to distinct tissue sites, both during steady-state conditions and in response to infection. Monocytes originate from progenitors in the bone marrow and traffic via the bloodstream to peripheral tissues. During both homeostasis and inflammation, circulating monocytes leave the bloodstream and migrate into tissues where, following conditioning by local growth factors, pro-inflammatory cytokines and microbial products, they differentiate into macrophage or dendritic cell populations. Recruitment of monocytes is essential for effective control and clearance of viral, bacterial, fungal and protozoal infections, but recruited monocytes also contribute to the pathogenesis of inflammatory and degenerative diseases. The mechanisms that control monocyte trafficking under homeostatic, infectious and inflammatory conditions are being unravelled and are the focus of this Review.

Changes in glycosylation during tumour progression are a key hallmark of cancer. One of the glycan moieties generally overexpressed in cancer are sialic acids, which can induce immunomodulatory properties via binding to Siglec receptors. We here show that Pancreatic Ductal Adenocarcinoma (PDAC) tumour cells present an increased sialylation that can be recognized by Siglec-7 and Siglec-9 on myeloid cells. We identified the expression of the α2,3 sialyltransferases ST3GAL1 and ST3GAL4 as main contributor to the synthesis of ligands for Siglec-7 and Siglec-9 in tumour cells. Analysing the myeloid composition in PDAC, using single cell and bulk transcriptomics data, we identified monocyte-derived macrophages as contributors to the poor clinical outcome. Tumour-derived sialic acids dictate monocyte to macrophage differentiation via signalling through Siglec-7 and Siglec-9. Moreover, triggering of Siglec-9 in macrophages reduce inflammatory programmes, while increasing PD-L1 and IL-10 expression, illustrating that sialic acids modulate different myeloid cells. This work highlights a critical role for sialylated glycans in controlling immune suppression and provides new potential targets for cancer immunotherapy in PDAC. Alterations in glycosylation in tumours facilitate tumour progression. Here, the authors show that pancreatic ductal adenocarcinomas present increased sialylation, which stimulates the polarisation of monocytes via Siglec receptors, resulting in the generation of immune suppressive tumour associated macrophages.